Forskning ved Københavns Universitet - Københavns Universitet

Forside

Clinical value of serum hyaluronan and propeptide of type III collagen in patients with pancreatic cancer

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Clinical value of serum hyaluronan and propeptide of type III collagen in patients with pancreatic cancer. / Chen, Inna M; Willumsen, Nicholas; Dehlendorff, Christian; Johansen, Astrid Z; Jensen, Benny V; Hansen, Carsten P; Hasselby, Jane P; Bojesen, Stig E; Pfeiffer, Per; Nielsen, Svend E; Holländer, Niels H; Yilmaz, Mette K; Karsdal, Morten; Johansen, Julia S.

I: International Journal of Cancer, Bind 146, Nr. 10, 2020, s. 2913-2922.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Chen, IM, Willumsen, N, Dehlendorff, C, Johansen, AZ, Jensen, BV, Hansen, CP, Hasselby, JP, Bojesen, SE, Pfeiffer, P, Nielsen, SE, Holländer, NH, Yilmaz, MK, Karsdal, M & Johansen, JS 2020, 'Clinical value of serum hyaluronan and propeptide of type III collagen in patients with pancreatic cancer', International Journal of Cancer, bind 146, nr. 10, s. 2913-2922. https://doi.org/10.1002/ijc.32751

APA

Chen, I. M., Willumsen, N., Dehlendorff, C., Johansen, A. Z., Jensen, B. V., Hansen, C. P., ... Johansen, J. S. (2020). Clinical value of serum hyaluronan and propeptide of type III collagen in patients with pancreatic cancer. International Journal of Cancer, 146(10), 2913-2922. https://doi.org/10.1002/ijc.32751

Vancouver

Chen IM, Willumsen N, Dehlendorff C, Johansen AZ, Jensen BV, Hansen CP o.a. Clinical value of serum hyaluronan and propeptide of type III collagen in patients with pancreatic cancer. International Journal of Cancer. 2020;146(10):2913-2922. https://doi.org/10.1002/ijc.32751

Author

Chen, Inna M ; Willumsen, Nicholas ; Dehlendorff, Christian ; Johansen, Astrid Z ; Jensen, Benny V ; Hansen, Carsten P ; Hasselby, Jane P ; Bojesen, Stig E ; Pfeiffer, Per ; Nielsen, Svend E ; Holländer, Niels H ; Yilmaz, Mette K ; Karsdal, Morten ; Johansen, Julia S. / Clinical value of serum hyaluronan and propeptide of type III collagen in patients with pancreatic cancer. I: International Journal of Cancer. 2020 ; Bind 146, Nr. 10. s. 2913-2922.

Bibtex

@article{3f90ec060e3b462e9dffe6f3921a578e,
title = "Clinical value of serum hyaluronan and propeptide of type III collagen in patients with pancreatic cancer",
abstract = "Hyaluronan (HA) and collagen are highly expressed in pancreatic cancer (PC) stroma. HA and collagen accumulation increase tumor interstitial fluid pressure, compromising blood flow and drug penetration. The aim of this biomarker study was to determine the clinical utility of serum HA and the propeptide of type III collagen (PRO-C3) in patients with PC. A cohort from the Danish BIOPAC study (NCT03311776) including patients with histologically confirmed pancreatic ductal adenocarcinoma (n = 809), ampullary carcinoma (n = 44), distal biliary tract cancer (n = 31), chronic pancreatitis (n = 15), intraductal papillary mucinous neoplasm (n = 41), duodenal adenoma (n = 7) and no cancer (n = 25). Healthy controls were available for serum HA (n = 141) and PRO-C3 (n = 8). The main outcome was overall survival (OS) of patients with PC in relation to pretreatment serum HA and PRO-C3 levels. Patients with PC had higher baseline serum HA and PRO-C3 than healthy subjects and patients with benign conditions. Pretreatment serum baseline HA and PRO-C3 in patients with PC were associated with poorer survival and PRO-C3 remained prognostic also after adjusting for age, performance status, stage, the presence of liver and peritoneum metastasis, and CA19-9. Detection of HA and PRO-C3 may be useful in differentiating between malignant and benign pancreatic conditions. Serum HA and PRO-C3 were prognostic for OS in patients with PC.",
author = "Chen, {Inna M} and Nicholas Willumsen and Christian Dehlendorff and Johansen, {Astrid Z} and Jensen, {Benny V} and Hansen, {Carsten P} and Hasselby, {Jane P} and Bojesen, {Stig E} and Per Pfeiffer and Nielsen, {Svend E} and Holl{\"a}nder, {Niels H} and Yilmaz, {Mette K} and Morten Karsdal and Johansen, {Julia S}",
note = "{\circledC} 2019 UICC.",
year = "2020",
doi = "10.1002/ijc.32751",
language = "English",
volume = "146",
pages = "2913--2922",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "JohnWiley & Sons, Inc.",
number = "10",

}

RIS

TY - JOUR

T1 - Clinical value of serum hyaluronan and propeptide of type III collagen in patients with pancreatic cancer

AU - Chen, Inna M

AU - Willumsen, Nicholas

AU - Dehlendorff, Christian

AU - Johansen, Astrid Z

AU - Jensen, Benny V

AU - Hansen, Carsten P

AU - Hasselby, Jane P

AU - Bojesen, Stig E

AU - Pfeiffer, Per

AU - Nielsen, Svend E

AU - Holländer, Niels H

AU - Yilmaz, Mette K

AU - Karsdal, Morten

AU - Johansen, Julia S

N1 - © 2019 UICC.

PY - 2020

Y1 - 2020

N2 - Hyaluronan (HA) and collagen are highly expressed in pancreatic cancer (PC) stroma. HA and collagen accumulation increase tumor interstitial fluid pressure, compromising blood flow and drug penetration. The aim of this biomarker study was to determine the clinical utility of serum HA and the propeptide of type III collagen (PRO-C3) in patients with PC. A cohort from the Danish BIOPAC study (NCT03311776) including patients with histologically confirmed pancreatic ductal adenocarcinoma (n = 809), ampullary carcinoma (n = 44), distal biliary tract cancer (n = 31), chronic pancreatitis (n = 15), intraductal papillary mucinous neoplasm (n = 41), duodenal adenoma (n = 7) and no cancer (n = 25). Healthy controls were available for serum HA (n = 141) and PRO-C3 (n = 8). The main outcome was overall survival (OS) of patients with PC in relation to pretreatment serum HA and PRO-C3 levels. Patients with PC had higher baseline serum HA and PRO-C3 than healthy subjects and patients with benign conditions. Pretreatment serum baseline HA and PRO-C3 in patients with PC were associated with poorer survival and PRO-C3 remained prognostic also after adjusting for age, performance status, stage, the presence of liver and peritoneum metastasis, and CA19-9. Detection of HA and PRO-C3 may be useful in differentiating between malignant and benign pancreatic conditions. Serum HA and PRO-C3 were prognostic for OS in patients with PC.

AB - Hyaluronan (HA) and collagen are highly expressed in pancreatic cancer (PC) stroma. HA and collagen accumulation increase tumor interstitial fluid pressure, compromising blood flow and drug penetration. The aim of this biomarker study was to determine the clinical utility of serum HA and the propeptide of type III collagen (PRO-C3) in patients with PC. A cohort from the Danish BIOPAC study (NCT03311776) including patients with histologically confirmed pancreatic ductal adenocarcinoma (n = 809), ampullary carcinoma (n = 44), distal biliary tract cancer (n = 31), chronic pancreatitis (n = 15), intraductal papillary mucinous neoplasm (n = 41), duodenal adenoma (n = 7) and no cancer (n = 25). Healthy controls were available for serum HA (n = 141) and PRO-C3 (n = 8). The main outcome was overall survival (OS) of patients with PC in relation to pretreatment serum HA and PRO-C3 levels. Patients with PC had higher baseline serum HA and PRO-C3 than healthy subjects and patients with benign conditions. Pretreatment serum baseline HA and PRO-C3 in patients with PC were associated with poorer survival and PRO-C3 remained prognostic also after adjusting for age, performance status, stage, the presence of liver and peritoneum metastasis, and CA19-9. Detection of HA and PRO-C3 may be useful in differentiating between malignant and benign pancreatic conditions. Serum HA and PRO-C3 were prognostic for OS in patients with PC.

U2 - 10.1002/ijc.32751

DO - 10.1002/ijc.32751

M3 - Journal article

C2 - 31642523

VL - 146

SP - 2913

EP - 2922

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 10

ER -

ID: 236017421